Skip to main content

Table 1 Inhibition of M. pneumoniae growth by nucleoside and nucleobase analogs*

From: Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs

Compounds Wild type MIC (μg ml-1) thyA mutant MIC (μg ml-1)
Ribavirin 62.5 > 500
Pentoxifylline 62.5 > 500
Gancyclovir 7.8 > 500
Zidovudine 7.8 7.8
Gemcitabine (dFdC) 2.4 2.4
Stavudine 7.8 17.8
Acyclovir 15.6 15.6
Pyrimethamine > 500 > 500
Fludarabine phosphate > 500 > 500
Lamivudine > 500 > 500
Mycophenolate mofetil 250 250
Trifluorothymidine (TFT) 1.8 1.8
Adefovir depivoxil > 500 > 500
5-azacytidine > 500 > 500
Azathioprine > 500 > 500
Arabinosyl adenine > 500 > 500
Zalcitabine > 500 > 500
5-iododeoxyuridine 15.6 > 500
5-fluorodeoxyuridine (5FdU) 7.8 15.6
Cidofovir 31.2 31.2
Caffeine > 500 > 500
7-(2,3-dihydroxypropyl)theophylline > 500 > 500
Theophylline > 500 > 500
6-thioguanine (6-TG) 0.2 0.2
Allopurinol > 500 > 500
6-mercaptopurine (6-MP) > 500 > 500
5-fluorouracil 31.2 31.2
5-fluorocytosine 31.2 31.2
Valacyclovir > 500 > 500
Dipyridamole 1.9 1.9
  1. *MIC = minimal concentrations of the compound that produced 90% inhibition.